Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 1,488 Cr.
- Current Price ₹ 286
- High / Low ₹ 354 / 224
- Stock P/E 43.7
- Book Value ₹ 48.0
- Dividend Yield 0.00 %
- ROCE 17.5 %
- ROE 14.7 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 33.1% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 132 | 151 | 158 | 140 | 223 | 190 | 219 | 249 | 301 | |
| 105 | 115 | 123 | 115 | 175 | 142 | 144 | 166 | 206 | |
| Operating Profit | 27 | 36 | 34 | 25 | 48 | 48 | 74 | 84 | 95 |
| OPM % | 20% | 24% | 22% | 18% | 22% | 25% | 34% | 34% | 32% |
| 1 | 1 | 2 | -1 | 2 | 1 | 1 | 4 | 4 | |
| Interest | 4 | 2 | 2 | 2 | 2 | 10 | 10 | 9 | 12 |
| Depreciation | 12 | 12 | 13 | 16 | 15 | 32 | 33 | 35 | 40 |
| Profit before tax | 12 | 23 | 21 | 6 | 33 | 8 | 33 | 44 | 47 |
| Tax % | 28% | 17% | 28% | -1% | 28% | 9% | 25% | 24% | 28% |
| 9 | 19 | 15 | 6 | 24 | 7 | 24 | 33 | 34 | |
| EPS in Rs | 130.00 | 276.09 | 220.43 | 93.77 | 344.20 | 104.20 | 353.33 | 6.42 | 6.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 17% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 59% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 16% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
| Reserves | 79 | 96 | 111 | 118 | 141 | 148 | 172 | 204 | 239 |
| 27 | 22 | 13 | 18 | 21 | 99 | 92 | 89 | 128 | |
| 33 | 43 | 42 | 28 | 32 | 29 | 30 | 30 | 72 | |
| Total Liabilities | 145 | 168 | 173 | 171 | 201 | 282 | 302 | 333 | 450 |
| 96 | 127 | 128 | 119 | 119 | 195 | 211 | 215 | 285 | |
| CWIP | 6 | 0 | 0 | 0 | 1 | 2 | 1 | 6 | 35 |
| Investments | 10 | 2 | 5 | 6 | 0 | 0 | 1 | 3 | 6 |
| 33 | 38 | 39 | 46 | 80 | 84 | 88 | 109 | 123 | |
| Total Assets | 145 | 168 | 173 | 171 | 201 | 282 | 302 | 333 | 450 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 31 | 24 | 42 | 45 | 61 | 63 | 80 | |||
| -20 | -28 | -44 | -22 | -35 | -39 | -51 | |||
| -10 | 3 | 1 | -24 | -26 | -24 | -28 | |||
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -1 | 1 | ||
| Free Cash Flow | 15 | 5 | 24 | 32 | 22 | 28 | 30 | ||
| CFO/OP | 111% | 100% | 97% | 109% | 94% | 88% | 99% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 14 | 16 | 12 | 9 | 15 | 22 | 30 |
| Inventory Days | 90 | 107 | 93 | 62 | 38 | 81 | 89 | 101 | 82 |
| Days Payable | 256 | 176 | 227 | 177 | 84 | 184 | 192 | 176 | 196 |
| Cash Conversion Cycle | -151 | -54 | -120 | -99 | -34 | -95 | -88 | -53 | -84 |
| Working Capital Days | -9 | 6 | -35 | -19 | -15 | -48 | -36 | -14 | -23 |
| ROCE % | 21% | 18% | 8% | 23% | 9% | 17% | 18% | 17% |
Insights
In beta| Dec 2007 | Dec 2010 | Dec 2016 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Number of Diagnostic Centres count |
|
|||||||
| Total Labs count |
||||||||
| Average Revenue Per Patient (ARPP) INR |
||||||||
| Average Revenue Per Test (ARPT) INR |
||||||||
| Number of Collection Centres count |
||||||||
| Number of Patients Served million |
||||||||
| Number of Tests Performed million |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2d - Transcript of the Earning Call held on Friday, 22 May 2026 with respect to the Audited (Standalone and Consolidated) Financial results of the Company for …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
22 May - Submitted Annual Secretarial Compliance Report for FY ended 31 March 2026; no non-compliances reported.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
22 May - Audio recording of 22 May 2026 earnings call for audited Q4 and FY26 results available on website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22 May - Newspaper publication of audited (standalone and consolidated) financial results of Company for quarter and financial year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
21 May - Suraksha Diagnostic posted FY26 results on 21 May 2026; total income rose 23% to ₹3,136 million.
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Dec 2024TranscriptAI SummaryPPT
Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 1,000+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.